Amgen Inc. (NASDAQ:AMGN) Shares Sold by XML Financial LLC

XML Financial LLC trimmed its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,167 shares of the medical research company’s stock after selling 361 shares during the quarter. XML Financial LLC’s holdings in Amgen were worth $5,778,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Capital Performance Advisors LLP purchased a new position in Amgen in the 3rd quarter valued at $25,000. Legacy Investment Solutions LLC purchased a new position in Amgen during the 3rd quarter worth $29,000. Hershey Financial Advisers LLC acquired a new stake in shares of Amgen in the 2nd quarter worth $30,000. Matrix Trust Co purchased a new stake in shares of Amgen in the third quarter valued at about $36,000. Finally, Livelsberger Financial Advisory acquired a new position in shares of Amgen during the third quarter worth about $56,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Up 1.0 %

Shares of AMGN stock opened at $274.81 on Wednesday. The company has a market capitalization of $147.72 billion, a price-to-earnings ratio of 35.19, a PEG ratio of 2.78 and a beta of 0.56. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The firm has a 50-day moving average price of $272.95 and a 200 day moving average price of $306.92. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same quarter in the previous year, the business posted $4.96 earnings per share. The company’s revenue was up 23.2% on a year-over-year basis. Research analysts forecast that Amgen Inc. will post 19.57 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.46%. Amgen’s dividend payout ratio (DPR) is 115.24%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on AMGN shares. William Blair restated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Royal Bank of Canada reduced their price target on Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a report on Wednesday, November 27th. Piper Sandler dropped their price objective on Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a report on Thursday, January 2nd. Jefferies Financial Group reissued a “buy” rating and issued a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. Finally, Barclays upped their price target on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research note on Monday, October 7th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.